​

Helus Pharma (HELP) Stock Forecast, Price Target & Predictions


OverviewChartTranscripts

HELP Stock Forecast


Helus Pharma (HELP) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $22.00, with a high of $35.00 and a low of $15.00. This represents a 205.56% increase from the last price of $7.20.

- $7 $14 $21 $28 $35 High: $35 Avg: $22 Low: $15 Last Closed Price: $7.2

HELP Stock Rating


Helus Pharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

HELP Price Target Upside V Benchmarks


TypeNameUpside
StockHelus Pharma205.56%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts-14
Avg Price Target-$35.00$22.00
Last Closing Price$7.20$7.20$7.20
Upside/Downside-386.11%205.56%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 26110---11
Oct, 26110---11
Sep, 26-10---10
Aug, 26-10---10
Jul, 26-9---9
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 18, 2026Barclays$35.00$12.99169.44%386.11%
Jul 27, 2026Wells Fargo$16.00$7.62109.97%122.22%
Jul 14, 2026Industrial Alliance Securities$15.00$6.68124.55%108.33%
Feb 01, 2026Andrew TsaiJefferies$22.00$6.62232.33%205.56%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Sep 18, 2026BarclaysOverweightinitialise
Aug 20, 2026Cowen & Co.BuyBuyhold
Jul 27, 2026Wells FargoOverweightinitialise
Jul 22, 2026H.C. WainwrightBuyBuyhold
Mar 05, 2026JefferiesBuyBuyhold
Feb 01, 2026JefferiesBuyinitialise

Financial Forecast


EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29 Mar 30
Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30
Reported$-0.61-----
Avg Forecast$-3.51$-3.12$-2.36$-2.39$-0.16$2.30
High Forecast$-3.51$-2.94$-2.36$-2.39$-0.16$2.30
Low Forecast$-3.51$-3.28$-2.36$-2.39$-0.16$2.30
Surprise %-82.62%-----

Revenue Forecast

$0 $170M $340M $510M $680M $850M Mar 25 Mar 26 Mar 27 Mar 28 Mar 29 Mar 30
Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30
Reported------
Avg Forecast--$31.70M$21.65M$386.70M$833.41M
High Forecast--$31.70M$21.65M$386.70M$833.41M
Low Forecast--$31.70M$21.65M$386.70M$833.41M
Surprise %------

Net Income Forecast

$-1B $-700M $-400M $-100M $200M $500M Mar 25 Mar 26 Mar 27 Mar 28 Mar 29 Mar 30
Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30
Reported$-113.14M-----
Avg Forecast$-650.01M$-578.38M$-438.37M$-443.20M$-29.22M$427.11M
High Forecast$-650.01M$-545.84M$-438.37M$-443.20M$-29.22M$427.11M
Low Forecast$-650.01M$-609.10M$-438.37M$-443.20M$-29.22M$427.11M
Surprise %-82.59%-----

HELP Forecast FAQ


Is Helus Pharma stock a buy?

Helus Pharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Helus Pharma is a favorable investment for most analysts.

What is Helus Pharma's price target?

Helus Pharma's price target, set by 5 Wall Street analysts, averages $22 over the next 12 months. The price target range spans from $15 at the low end to $35 at the high end, suggesting a potential 205.56% change from the previous closing price of $7.2.

How does Helus Pharma stock forecast compare to its benchmarks?

Helus Pharma's stock forecast shows a 205.56% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Helus Pharma over the past three months?

  • November 2026: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Helus Pharma’s EPS forecast?

Helus Pharma's average annual EPS forecast for its fiscal year ending in March 2026 is $-3.12, marking a 411.48% increase from the reported $-0.61 in 2025. Estimates for the following years are $-2.36 in 2027, $-2.39 in 2028, $-0.16 in 2029, and $2.3 in 2030.

What is Helus Pharma’s revenue forecast?

Helus Pharma's average annual revenue forecast for its fiscal year ending in March 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $31.7M, followed by $21.65M for 2028, $386.7M for 2029, and $833.41M for 2030.

What is Helus Pharma’s net income forecast?

Helus Pharma's net income forecast for the fiscal year ending in March 2026 stands at $-578M, representing an 411.22% increase from the reported $-113M in 2025. Projections indicate $-438M in 2027, $-443M in 2028, $-29.218M in 2029, and $427.11M in 2030.